Cargando…
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
BACKGROUND: In order to estimate utilities for cancer studies where the EQ-5D was not used, the EORTC QLQ-C30 can be used to estimate EQ-5D using existing mapping algorithms. Several mapping algorithms exist for this transformation, however, algorithms tend to lose accuracy in patients in poor healt...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316600/ https://www.ncbi.nlm.nih.gov/pubmed/25613110 http://dx.doi.org/10.1186/s12955-014-0196-y |
_version_ | 1782355587250520064 |
---|---|
author | Arnold, David T Rowen, Donna Versteegh, Matthijs M Morley, Anna Hooper, Clare E Maskell, Nicholas A |
author_facet | Arnold, David T Rowen, Donna Versteegh, Matthijs M Morley, Anna Hooper, Clare E Maskell, Nicholas A |
author_sort | Arnold, David T |
collection | PubMed |
description | BACKGROUND: In order to estimate utilities for cancer studies where the EQ-5D was not used, the EORTC QLQ-C30 can be used to estimate EQ-5D using existing mapping algorithms. Several mapping algorithms exist for this transformation, however, algorithms tend to lose accuracy in patients in poor health states. The aim of this study was to test all existing mapping algorithms of QLQ-C30 onto EQ-5D, in a dataset of patients with malignant pleural mesothelioma, an invariably fatal malignancy where no previous mapping estimation has been published. METHODS: Health related quality of life (HRQoL) data where both the EQ-5D and QLQ-C30 were used simultaneously was obtained from the UK-based prospective observational SWAMP (South West Area Mesothelioma and Pemetrexed) trial. In the original trial 73 patients with pleural mesothelioma were offered palliative chemotherapy and their HRQoL was assessed across five time points. This data was used to test the nine available mapping algorithms found in the literature, comparing predicted against observed EQ-5D values. The ability of algorithms to predict the mean, minimise error and detect clinically significant differences was assessed. RESULTS: The dataset had a total of 250 observations across 5 timepoints. The linear regression mapping algorithms tested generally performed poorly, over-estimating the predicted compared to observed EQ-5D values, especially when observed EQ-5D was below 0.5. The best performing algorithm used a response mapping method and predicted the mean EQ-5D with accuracy with an average root mean squared error of 0.17 (Standard Deviation; 0.22). This algorithm reliably discriminated between clinically distinct subgroups seen in the primary dataset. CONCLUSIONS: This study tested mapping algorithms in a population with poor health states, where they have been previously shown to perform poorly. Further research into EQ-5D estimation should be directed at response mapping methods given its superior performance in this study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12955-014-0196-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4316600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43166002015-02-05 Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma Arnold, David T Rowen, Donna Versteegh, Matthijs M Morley, Anna Hooper, Clare E Maskell, Nicholas A Health Qual Life Outcomes Research BACKGROUND: In order to estimate utilities for cancer studies where the EQ-5D was not used, the EORTC QLQ-C30 can be used to estimate EQ-5D using existing mapping algorithms. Several mapping algorithms exist for this transformation, however, algorithms tend to lose accuracy in patients in poor health states. The aim of this study was to test all existing mapping algorithms of QLQ-C30 onto EQ-5D, in a dataset of patients with malignant pleural mesothelioma, an invariably fatal malignancy where no previous mapping estimation has been published. METHODS: Health related quality of life (HRQoL) data where both the EQ-5D and QLQ-C30 were used simultaneously was obtained from the UK-based prospective observational SWAMP (South West Area Mesothelioma and Pemetrexed) trial. In the original trial 73 patients with pleural mesothelioma were offered palliative chemotherapy and their HRQoL was assessed across five time points. This data was used to test the nine available mapping algorithms found in the literature, comparing predicted against observed EQ-5D values. The ability of algorithms to predict the mean, minimise error and detect clinically significant differences was assessed. RESULTS: The dataset had a total of 250 observations across 5 timepoints. The linear regression mapping algorithms tested generally performed poorly, over-estimating the predicted compared to observed EQ-5D values, especially when observed EQ-5D was below 0.5. The best performing algorithm used a response mapping method and predicted the mean EQ-5D with accuracy with an average root mean squared error of 0.17 (Standard Deviation; 0.22). This algorithm reliably discriminated between clinically distinct subgroups seen in the primary dataset. CONCLUSIONS: This study tested mapping algorithms in a population with poor health states, where they have been previously shown to perform poorly. Further research into EQ-5D estimation should be directed at response mapping methods given its superior performance in this study. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12955-014-0196-y) contains supplementary material, which is available to authorized users. BioMed Central 2015-01-23 /pmc/articles/PMC4316600/ /pubmed/25613110 http://dx.doi.org/10.1186/s12955-014-0196-y Text en © Arnold et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Arnold, David T Rowen, Donna Versteegh, Matthijs M Morley, Anna Hooper, Clare E Maskell, Nicholas A Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title | Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title_full | Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title_fullStr | Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title_full_unstemmed | Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title_short | Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma |
title_sort | testing mapping algorithms of the cancer-specific eortc qlq-c30 onto eq-5d in malignant mesothelioma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316600/ https://www.ncbi.nlm.nih.gov/pubmed/25613110 http://dx.doi.org/10.1186/s12955-014-0196-y |
work_keys_str_mv | AT arnolddavidt testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma AT rowendonna testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma AT versteeghmatthijsm testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma AT morleyanna testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma AT hooperclaree testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma AT maskellnicholasa testingmappingalgorithmsofthecancerspecificeortcqlqc30ontoeq5dinmalignantmesothelioma |